FDA Approves Merck’s Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors

All NewsMay 14, 2025

Merck’s Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent